从概念框架的形成到监管决策:考虑患者报告结果工具的发展
Kai Cao1,2, Xu-Yuan Quan1, Yan Hou1,3,4
1Department of Biostatistics, School of Public Health, Peking University, Beijing, 100191, People's Republic of China.
Drug design, development and therapy
|December 11, 2024
概括
以患者为中心的药物开发 (PFDD) 通过将患者作为合作伙伴,改变了临床试验. 这种以患者报告结果 (PROs) 为中心的方法增强了药物开发和监管审查.
科学领域:
- 临床试验方法论 临床试验方法论
- 监管科学是一种监管科学.
- 让患者参与到研究中.
背景情况:
- 患者为中心的药物开发 (PFDD) 是临床试验中的一个新兴范式.
- PFDD将患者纳入研究设计,实施和结果评估中的积极合作伙伴.
- 美国,中国和欧洲的监管政策支持PFDD原则.
研究的目的:
- 审查患者报告的结果 (PRO) 作为PFDD临床结果评估 (COA) 的核心组成部分.
- 探索PRO工具的开发,应用和监管纳入.
- 突出PROs在制药研究和药物批准中的重要性.
主要方法:
- 关于PFDD原则和监管指南的文献综述.
- 分析临床结果评估 (COA) 和患者报告结果 (PRO) 的作用.
- 检查PRO仪器开发和合格流程,特别是美国FDA.
主要成果:
- PFDD加速了患者的招生,并提高了药物批准成功率.
- 患者报告的结果 (PRO) 是最常见的COA类型,并越来越多地被监管机构认可.
- 许多COA工具,主要是PRO,正在接受美国FDA等监管机构的资格审查.
结论:
- 患者报告的结果对于有效的以患者为中心的药物开发至关重要.
- 标准化的开发和PRO工具的严格应用对于监管接受至关重要.
- 由PRO驱动的PFDD代表了制药研究和患者护理的重大进步.
相关概念视频
Guidelines for Writing Outcome
2.7K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
2.7K
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
Drug Control Governance: Regulatory Bodies and Their Impact
141
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
141


